Severe thrombocytopenia and mild leucopenia associated with deferasirox therapy;Thrombocytopénie sévére et leucopénie modérée sous déférasirox (Exjade®)

Therapie

Volumn 64, Issue 6, 2009, Pages 405-407

  Grandvuillemin, Aurélie ^a   Audia, Sylvain ^b   Leguy Seguin, Vanessa ^b   Coullet, Valérie ^a   Bonnotte, Bernard ^b   Sgro, Catherine ^a  

^a Regional Pharmacovigilance Center   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; DEFERASIROX; ERYTHROPOIETIN; FOLIC ACID; GABAPENTIN; HEMOSIDERIN; OXCARBAZEPINE; SPECIAFOLDINE; THIAMINE; TOPIRAMATE; UNCLASSIFIED DRUG;

ADULT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW DISEASE; CASE REPORT; CHROMOSOME 20Q; CHROMOSOME DELETION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSERYTHROPOIESIS; DYSLIPIDEMIA; DYSMEGACARYOPOIESIS; HEAD INJURY; HEMIPLEGIA; HEMOCHROMATOSIS; HIP OSTEOARTHRITIS; HISTIOCYTE; HUMAN; HYPERPLASIA; HYPERTENSION; IRON CHELATION; ISCHEMIC HEART DISEASE; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; MYELOFIBROSIS; PRIORITY JOURNAL; RELAPSE; SIDEROBLASTIC ANEMIA; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 73649147048     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2009059     Document Type: Article

References (13)

1. Résumé des Caractéristiques du Produit édition Vidal® 2009
2. Health Canada. Important safety information on Exjade® (deferasirox), 9 mars 2007. http://www.hc-sc.gc.ca/dhp-mps/medeff/index-fra.php
3. Food and Drug Administration. Important safety information about Exjade® (deferasirox), 14 mai 2007. http://www.fda. gov/downloads/Safety/ MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/UCM154395.pdf
4. European Medicines Agency. Procedural steps taken and scientific information after the authorisation, 2009. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/exjade/H-670-en8.pdf
5. List Alan F, Baer MR, Steensma D, et al. Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma uron (LPI) in patients with myelodysplastic syndromes (MDS). American Society of Hematology Annual Meeting Abstracts: Abstract 1470. Blood 2007; 110
6. Sheikh-Taha M, Koussa S, Taher A. Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient. Haematologica 2006; 91(6 suppl): ECR25
7. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassemics. Eur J Haematol 2005; 74(3): 217-220
8. Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anemia during oral chelator trial. Lancet 1989; 2(8660): 457
9. Alter BP. Agranulocytosis and thrombocytopenia, Blackfan-Diamond anemia, and oral chelation. Lancet 1990; 335(8695): 970
10. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Br J Haematol 1990; 76(2): 301-304
11. Walker JA, Sherman RA, Eisinger RP. Thrombocytopenia associated with intravenous desferrioxamine. Am J Kidney Dis 1985; 6(4): 254-256
12. Sofroniadou K, Drossou M, Foundoulaki L, et al. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf 1990; 5(2): 152-154
13. Vlachaki E, Ioannidou-Papagiannaki E, Tziomalos K, et al. Peripheral blood haematopoietic progenitor cells in patients with beta thalassemia major receiving desferrioxamine or deferiprone as chelation therapy. Eur J Haematol 2007; 78(1): 48-51